BRPI0406692A - Implante ocular biodegradável - Google Patents

Implante ocular biodegradável

Info

Publication number
BRPI0406692A
BRPI0406692A BR0406692-8A BRPI0406692A BRPI0406692A BR PI0406692 A BRPI0406692 A BR PI0406692A BR PI0406692 A BRPI0406692 A BR PI0406692A BR PI0406692 A BRPI0406692 A BR PI0406692A
Authority
BR
Brazil
Prior art keywords
biodegradable
eye implant
implants
eye
release
Prior art date
Application number
BR0406692-8A
Other languages
English (en)
Inventor
Thierry Nivaggioli
Lin Peng
David Chou
David Weber
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Priority to BR122015016901A priority Critical patent/BR122015016901B8/pt
Publication of BRPI0406692A publication Critical patent/BRPI0406692A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/204—Polyesters, e.g. poly(lactide-co-glycolide)

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Prostheses (AREA)

Abstract

"IMPLANTE OCULAR BIODEGRADáVEL". A presente invenção refere-se a implantes biodegradáveis talhados para implantação na região ocular e processos para tratamento de condições médicas do olho. Os implantes são formados a partir de uma mistura de PLGA de extremidade hidrofílica e hidrofóbica, e liberam agentes ativos em uma região ocular sem uma alta explosão de liberação.
BR0406692-8A 2003-01-09 2004-01-07 Implante ocular biodegradável BRPI0406692A (pt)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BR122015016901A BR122015016901B8 (pt) 2003-01-09 2004-01-07 implante de bioerosão para tratamento de uma condição médica do olho humano compreendendo dexametasona

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/340,237 US20040137059A1 (en) 2003-01-09 2003-01-09 Biodegradable ocular implant
PCT/US2004/000351 WO2004062649A2 (en) 2003-01-09 2004-01-07 Biodegradable ocular implant

Publications (1)

Publication Number Publication Date
BRPI0406692A true BRPI0406692A (pt) 2005-12-20

Family

ID=32711277

Family Applications (2)

Application Number Title Priority Date Filing Date
BR0406692-8A BRPI0406692A (pt) 2003-01-09 2004-01-07 Implante ocular biodegradável
BR122015016901A BR122015016901B8 (pt) 2003-01-09 2004-01-07 implante de bioerosão para tratamento de uma condição médica do olho humano compreendendo dexametasona

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR122015016901A BR122015016901B8 (pt) 2003-01-09 2004-01-07 implante de bioerosão para tratamento de uma condição médica do olho humano compreendendo dexametasona

Country Status (20)

Country Link
US (1) US20040137059A1 (pt)
EP (6) EP2799064B1 (pt)
JP (1) JP4223040B2 (pt)
KR (1) KR20050099008A (pt)
CN (2) CN101259280A (pt)
AT (1) ATE555779T1 (pt)
AU (1) AU2004204744B2 (pt)
BR (2) BRPI0406692A (pt)
CA (1) CA2512315C (pt)
CY (4) CY1118431T1 (pt)
DK (5) DK3187177T3 (pt)
ES (5) ES2384875T3 (pt)
FR (1) FR12C0067I1 (pt)
HU (4) HUE030319T2 (pt)
MX (1) MXPA05007342A (pt)
NZ (1) NZ540451A (pt)
PT (4) PT3187177T (pt)
SI (3) SI2799064T1 (pt)
TR (2) TR201802793T4 (pt)
WO (1) WO2004062649A2 (pt)

Families Citing this family (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869079A (en) * 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US20060280774A1 (en) * 1995-06-02 2006-12-14 Allergan, Inc. Compositions and methods for treating glaucoma
US6726918B1 (en) 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
EP1339438B1 (en) * 2000-11-29 2005-10-19 Allergan Inc. Preventing transplant rejection in the eye
US7431710B2 (en) 2002-04-08 2008-10-07 Glaukos Corporation Ocular implants with anchors and methods thereof
US20130041025A1 (en) 2002-02-04 2013-02-14 Allergan, Inc. Compositions and methods for treating hair loss, hair thinning, and hair color loss
US20050048099A1 (en) * 2003-01-09 2005-03-03 Allergan, Inc. Ocular implant made by a double extrusion process
CA2524271C (en) 2003-05-02 2012-09-04 Surmodics, Inc. Controlled release bioactive agent delivery device
US8246974B2 (en) 2003-05-02 2012-08-21 Surmodics, Inc. Medical devices and methods for producing the same
US7060723B2 (en) * 2003-08-29 2006-06-13 Allergan, Inc. Treating neurological disorders using selective antagonists of persistent sodium current
US7125908B2 (en) * 2003-08-29 2006-10-24 Allergan, Inc. Treating pain using selective antagonists of persistent sodium current
US20070224278A1 (en) 2003-11-12 2007-09-27 Lyons Robert T Low immunogenicity corticosteroid compositions
US20050101582A1 (en) 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
DE602005011928D1 (de) 2004-01-20 2009-02-05 Allergan Inc Zusammensetzungen für die lokalisierte therapie des auges, vorzugsweise enthaltend triamcinolon-acetonid und hyaluronsäure
US8119154B2 (en) 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
US20050244466A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Photodynamic therapy in conjunction with intraocular implants
US9498457B2 (en) 2004-04-30 2016-11-22 Allergan, Inc. Hypotensive prostamide-containing biodegradable intraocular implants and related implants
US20050244458A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular neuropathies
US8425929B2 (en) * 2004-04-30 2013-04-23 Allergan, Inc. Sustained release intraocular implants and methods for preventing retinal dysfunction
US8685435B2 (en) 2004-04-30 2014-04-01 Allergan, Inc. Extended release biodegradable ocular implants
US20050244461A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Controlled release drug delivery systems and methods for treatment of an eye
US8147865B2 (en) 2004-04-30 2012-04-03 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
WO2005110374A1 (en) * 2004-04-30 2005-11-24 Allergan, Inc. Intraocular drug delivery systems containing a therapeutic component, a cyclodextrin, and a polymeric component
US8722097B2 (en) 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US8673341B2 (en) 2004-04-30 2014-03-18 Allergan, Inc. Intraocular pressure reduction with intracameral bimatoprost implants
US7993634B2 (en) 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US20050244469A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
CN101115475A (zh) * 2004-12-10 2008-01-30 塔利马治疗公司 用于治疗指甲单位病症的组合物和方法
US20060275230A1 (en) 2004-12-10 2006-12-07 Frank Kochinke Compositions and methods for treating conditions of the nail unit
AU2011236024B2 (en) * 2005-03-01 2013-05-23 Allergan, Inc. Microimplants for ocular administration
US20060204548A1 (en) * 2005-03-01 2006-09-14 Allergan, Inc. Microimplants for ocular administration
US20090082321A1 (en) * 2007-09-21 2009-03-26 Allergan, Inc. Steroid containing drug delivery systems
US20070178138A1 (en) * 2006-02-01 2007-08-02 Allergan, Inc. Biodegradable non-opthalmic implants and related methods
US20070260203A1 (en) * 2006-05-04 2007-11-08 Allergan, Inc. Vasoactive agent intraocular implant
US8802128B2 (en) * 2006-06-23 2014-08-12 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
EP1917971A1 (en) * 2006-10-27 2008-05-07 Société de Conseils de Recherches et d'Applications Scientifiques ( S.C.R.A.S.) Substained release formulations comprising very low molecular weight polymers
US8969415B2 (en) * 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
US8536190B2 (en) * 2007-01-30 2013-09-17 Allergan, Inc. Treating unwanted ocular conditions using an ascomycin macrolactam
WO2008113043A1 (en) * 2007-03-14 2008-09-18 University Of Washington Device and method for intraocular drug delivery
US20080317805A1 (en) * 2007-06-19 2008-12-25 Mckay William F Locally administrated low doses of corticosteroids
DK2207529T3 (en) * 2007-09-07 2015-03-09 Mati Therapeutics Inc PHARMACEUTICAL cores for the sustained release of therapeutic agents
US8353862B2 (en) 2007-11-02 2013-01-15 Allergan, Inc. Drug delivery systems and methods
US8524267B2 (en) * 2008-04-18 2013-09-03 Warsaw Orthopedic, Inc. Dexamethasone formulations in a biodegradable material
US9125917B2 (en) * 2008-04-18 2015-09-08 Warsaw Orthopedic, Inc. Fluocinolone formulations in a biodegradable polymer carrier
US9877973B2 (en) 2008-05-12 2018-01-30 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US9095404B2 (en) 2008-05-12 2015-08-04 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US10588855B2 (en) 2008-05-12 2020-03-17 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
AU2009246520B2 (en) 2008-05-12 2012-04-19 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US10064819B2 (en) 2008-05-12 2018-09-04 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US20110206773A1 (en) * 2008-05-20 2011-08-25 Yale University Sustained delivery of drugs from biodegradable polymeric microparticles
EP2296621A1 (en) * 2008-05-20 2011-03-23 Yale University Biodegradable sustained-release polymeric microparticulates comprising a hydrophobic drug and determined for ophthalmic use
CN101612111B (zh) * 2008-06-24 2011-11-23 上海医药工业研究院 醋酸诺美孕酮或其类似物的缓释微球及其制备方法和用途
US10842669B2 (en) 2008-11-13 2020-11-24 Gholam A. Peyman Ophthalmic drug delivery method
US20110125090A1 (en) * 2008-11-13 2011-05-26 Peyman Gholam A Ophthalmic drug delivery system and method
US10272035B2 (en) 2008-11-13 2019-04-30 Gholam A. Peyman Ophthalmic drug delivery method
US20100204325A1 (en) * 2009-02-11 2010-08-12 Allergan, Inc. Valproic acid drug delivery systems and intraocular therapeutic uses thereof
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
US12478503B2 (en) 2009-05-18 2025-11-25 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
EP2432420A4 (en) 2009-05-18 2018-01-10 Dose Medical Corporation Drug eluting ocular implant
US20100303783A1 (en) * 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Urogenital-Neurological Disorders Using Tachykinin Retargeted Endopepidases
US20100303788A1 (en) * 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Chronic Neurogenic Inflammation Using Galanin Retargeted Endopepidases
US20100303757A1 (en) 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Chronic Neurogenic Inflammation Using Interleukin Retargeted Endopepidases
US20100303794A1 (en) 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Urogenital-Neurological Disorders Using Glucagon Like Hormone Retargeted Endopepidases
CA2771154A1 (en) 2009-08-14 2011-02-17 Allergan, Inc. Methods of treating cancer using opioid retargeted endpeptidases
AU2010282276A1 (en) 2009-08-14 2012-03-15 Allergan, Inc. Methods of treating cancer using neurotrophin retargeted endopeptidases
CN102574899A (zh) 2009-08-14 2012-07-11 阿勒根公司 使用胰高血糖素样激素再靶向内肽酶治疗癌症的方法
CN102573876A (zh) * 2009-08-14 2012-07-11 阿勒根公司 使用甘丙肽再靶向内肽酶治疗癌症的方法
EP2464366A2 (en) 2009-08-14 2012-06-20 Allergan, Inc. Methods of treating cancer using growth factor retargeted endopeptidases
WO2011020114A2 (en) 2009-08-14 2011-02-17 Allergan, Inc. Methods of treating cancer using tachykinin retargeted endopeptidases
KR20130020881A (ko) 2010-02-08 2013-03-04 알러간, 인코포레이티드 칸나비노이드-2 효능제로서 유용한 피리다진 유도체
EP2654715B1 (en) 2010-11-24 2017-01-25 Dose Medical Corporation Drug eluting ocular implant
US8349005B2 (en) 2011-01-03 2013-01-08 Masatoshi Murata Method for burying implant to choroid
WO2012112434A1 (en) 2011-02-14 2012-08-23 Allergan, Inc. Inhibiting aberrant blood vessel formation using retargeted endopeptidases
US20120207733A1 (en) 2011-02-14 2012-08-16 Allergan, Inc. Treating a Disease of Hyperproliferation Using Retargeted Endopeptidases
WO2012112420A1 (en) 2011-02-14 2012-08-23 Allergan, Inc. Treatments using psma ligand endopeptidases
WO2012112432A1 (en) 2011-02-14 2012-08-23 Allergan, Inc. Methods of inhibiting aberrant blood vessel formation using opioid retargeted endopeptidases
WO2012112422A1 (en) 2011-02-14 2012-08-23 Allergan, Inc. Inhibiting aberrant blood vessel formation using growth factor retargeted endopeptidases
US10245178B1 (en) 2011-06-07 2019-04-02 Glaukos Corporation Anterior chamber drug-eluting ocular implant
US9827401B2 (en) 2012-06-01 2017-11-28 Surmodics, Inc. Apparatus and methods for coating medical devices
MX351261B (es) 2012-06-01 2017-10-06 Surmodics Inc Aparato y método para recubrir catéteres con globo.
WO2014066644A1 (en) 2012-10-26 2014-05-01 Allergan, Inc. Ketorolac-containing sustained release drug delivery systems
CN112932781A (zh) * 2013-01-15 2021-06-11 科罗拉多州立大学董事会, 公司实体 泪腺系统给药装置
CN105377355A (zh) 2013-03-14 2016-03-02 拇趾公司 治疗甲单元的感染、疾病或病症的方法
PT3062775T (pt) * 2013-10-31 2018-03-06 Allergan Inc Implantes intraoculares contendo prostamida e métodos para a sua utilização
EP3110375B1 (en) * 2014-02-26 2022-01-26 Allergan, Inc. Intraocular implant delivery apparatus
AU2015266850B2 (en) 2014-05-29 2019-12-05 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
RU2687176C2 (ru) 2014-09-11 2019-05-07 Айпоинт Фармасьютикалз Юэс, Инк. Инъекционное устройство
FR3028410A1 (fr) 2014-11-18 2016-05-20 Pierre Coulon Implant capsulaire multifonctionnel
WO2017040853A1 (en) 2015-09-02 2017-03-09 Glaukos Corporation Drug delivery implants with bi-directional delivery capacity
WO2017053885A1 (en) 2015-09-25 2017-03-30 Glaukos Corporation Punctal implants with controlled drug delivery features and methods of using same
USD851755S1 (en) 2015-10-22 2019-06-18 Eyepoint Pharmaceuticals Us, Inc. Ocular inserter
AU2016359288C1 (en) 2015-11-23 2022-03-17 The Regents Of The University Of Colorado, A Body Corporate Lacrimal system for drug delivery
AU2017252294B2 (en) 2016-04-20 2021-12-02 Glaukos Corporation Bioresorbable ocular drug delivery device
WO2017201255A1 (en) 2016-05-20 2017-11-23 The Regents Of The University Of Colorado, A Body Corporate Lacrimal drug delivery device
EP3515406B1 (en) 2016-09-23 2024-07-24 Incept, LLC Intracameral drug delivery depots
WO2020112816A1 (en) 2018-11-29 2020-06-04 Surmodics, Inc. Apparatus and methods for coating medical devices
US12576035B2 (en) * 2019-02-01 2026-03-17 The University Of North Carolina At Chapel Hill Polymeric implants with high drug loading and long-acting drug release and methods of making the same
US11819590B2 (en) 2019-05-13 2023-11-21 Surmodics, Inc. Apparatus and methods for coating medical devices
US12403291B2 (en) 2019-08-30 2025-09-02 Intersect Ent, Inc. Submucosal bioresorbable drug eluting platform
US12496612B2 (en) 2021-01-08 2025-12-16 Surmodics, Inc. Coating application system and methods for coating rotatable medical devices

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0052916B1 (en) * 1980-11-10 1985-01-02 Alza Corporation Erodible polymer containing erosion rate modifier
US4322323A (en) * 1980-12-01 1982-03-30 Alza Corporation Erodible device comprising surfactant for modifying the rate of erosion of the device
US4883457A (en) * 1983-08-18 1989-11-28 Drug Delivery Systems Inc. Disposable and/or replenishable transdermal drug applicators and methods of manufacturing same
US6309669B1 (en) * 1984-03-16 2001-10-30 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix
US6217911B1 (en) * 1995-05-22 2001-04-17 The United States Of America As Represented By The Secretary Of The Army sustained release non-steroidal, anti-inflammatory and lidocaine PLGA microspheres
US4863457A (en) 1986-11-24 1989-09-05 Lee David A Drug delivery device
JPS63291419A (ja) * 1987-05-24 1988-11-29 Tatsumo Kk 加熱処理装置
US4853224A (en) * 1987-12-22 1989-08-01 Visionex Biodegradable ocular implants
US4997652A (en) * 1987-12-22 1991-03-05 Visionex Biodegradable ocular implants
US5164188A (en) 1989-11-22 1992-11-17 Visionex, Inc. Biodegradable ocular implants
KR0185215B1 (ko) * 1990-11-30 1999-05-01 요시다 쇼오지 서방성 안구삽입용 약제
US5378475A (en) * 1991-02-21 1995-01-03 University Of Kentucky Research Foundation Sustained release drug delivery devices
ATE195065T1 (de) 1993-02-26 2000-08-15 Santen Pharmaceutical Co Ltd Biologisch abbaubarer sklerastopfen
US5707643A (en) * 1993-02-26 1998-01-13 Santen Pharmaceutical Co., Ltd. Biodegradable scleral plug
US5443505A (en) * 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
US5869079A (en) * 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US6369116B1 (en) * 1995-06-02 2002-04-09 Oculex Pharmaceuticals, Inc. Composition and method for treating glaucoma
WO1997026869A1 (en) * 1996-01-24 1997-07-31 United States Government Represented By The Secretary Of The Army Novel 'burst-free' sustained release poly-(lactide/glycolide) microspheres
KR20010014384A (ko) * 1997-07-02 2001-02-26 모리타 다카카즈 폴리락트산 공막 플러그
US6306426B1 (en) * 1997-08-11 2001-10-23 Allergan Sales, Inc. Implant device with a retinoid for improved biocompatibility
US6217895B1 (en) * 1999-03-22 2001-04-17 Control Delivery Systems Method for treating and/or preventing retinal diseases with sustained release corticosteroids
US6726918B1 (en) * 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
EP1339438B1 (en) * 2000-11-29 2005-10-19 Allergan Inc. Preventing transplant rejection in the eye

Also Published As

Publication number Publication date
DK1581193T3 (da) 2012-06-25
EP3187177A1 (en) 2017-07-05
PT3305284T (pt) 2019-08-30
EP1581193A2 (en) 2005-10-05
SI3187177T1 (sl) 2019-09-30
ES2742152T3 (es) 2020-02-13
CY1121912T1 (el) 2020-10-14
CY1120147T1 (el) 2018-12-12
EP2799064A1 (en) 2014-11-05
NZ540451A (en) 2008-02-29
CY1121731T1 (el) 2020-07-31
ES2735132T3 (es) 2019-12-16
HUE036209T2 (hu) 2018-06-28
EP1581193B1 (en) 2012-05-02
KR20050099008A (ko) 2005-10-12
CA2512315C (en) 2008-12-30
MXPA05007342A (es) 2005-09-30
WO2004062649A3 (en) 2004-11-04
CY1118431T1 (el) 2017-06-28
ES2384875T3 (es) 2012-07-13
DK3305284T3 (da) 2019-08-19
BR122015016901B8 (pt) 2021-07-27
ES2661383T3 (es) 2018-03-28
SI3305284T1 (sl) 2019-11-29
AU2004204744B2 (en) 2008-03-13
TR201908857T4 (tr) 2019-07-22
DK2799064T3 (en) 2018-03-12
FR12C0067I1 (fr) 2012-12-14
WO2004062649A2 (en) 2004-07-29
EP3305284B1 (en) 2019-05-15
US20040137059A1 (en) 2004-07-15
DK3187177T3 (da) 2019-06-24
CA2512315A1 (en) 2004-07-29
EP1917957A3 (en) 2011-06-15
PT3187177T (pt) 2019-06-27
HUE044694T2 (hu) 2019-11-28
EP1917957A2 (en) 2008-05-07
EP1917957B1 (en) 2016-11-16
TR201802793T4 (tr) 2018-03-21
EP3563839A1 (en) 2019-11-06
AU2004204744A1 (en) 2004-07-29
ATE555779T1 (de) 2012-05-15
DK1917957T3 (en) 2017-02-13
HUE044965T2 (hu) 2019-11-28
BR122015016901B1 (pt) 2018-06-05
CN101259280A (zh) 2008-09-10
JP4223040B2 (ja) 2009-02-12
ES2613028T3 (es) 2017-05-22
PT2799064T (pt) 2018-03-06
EP2799064B1 (en) 2017-11-29
JP2006525953A (ja) 2006-11-16
CN1735405A (zh) 2006-02-15
HUE030319T2 (en) 2017-05-29
EP3187177B1 (en) 2019-03-20
CN100364514C (zh) 2008-01-30
PT1917957T (pt) 2017-01-23
SI2799064T1 (en) 2018-04-30
EP3305284A1 (en) 2018-04-11
HK1084021A1 (en) 2006-07-21

Similar Documents

Publication Publication Date Title
BRPI0406692A (pt) Implante ocular biodegradável
BRPI0513849B8 (pt) implante ocular fabricado por um processo de extrusão dupla
BRPI0510439A (pt) implantes intraoculares de liberação sustentada contendo macromoléculas e métodos relacionados
AU2013363325B2 (en) Capsule expander devices, systems, and methods for inhibiting capsular opacification and stabilizing the capsule
US9220590B2 (en) Accommodative intraocular lens and method of improving accommodation
WO2010059214A3 (en) Biocompatible biodegradable intraocular implant system
RU2012133880A (ru) Внутрикамерные имплантаты с пролонгированным высвобождением терапевтического агента
CA2656523A1 (en) Flexible bioresorbable hemostatic packing and stent
WO2001070289A3 (en) Injectable and swellable microspheres for tissue bulking
DK0654256T3 (da) Bionedbrydelig senehindetampon
BR0209327A (pt) Composição para tratamento de constipação induzida por drogas
SE0403092D0 (sv) Amphiphilic block copolymers and their use
MD3247F1 (ro) Metoda de tratament al cataractei senile
RU2000119720A (ru) Способ предотвращения дислокации силикона в переднюю камеру при хирургическом лечении рецидивирующих отслоек сетчатки
WO2019169835A1 (zh) 一种泪小管栓
UA40313A (uk) Спосіб видалення підвивихнутого кришталика з наступною імплантацією штучного кришталика
ITPR20010074A1 (it) Ancoretta boma (ancoretta modulare in metallo per interventi chirurgici).

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8, 13 E 25 DA LPI

B12B Appeal against refusal [chapter 12.2 patent gazette]